Processa Pharmaceuticals, Inc. (PCSA) M&A Call Prepared Remarks Transcript

Operator

Thank you for standing by. My name is Demi, and I’ll be your conference operator today. At this time, I would like to welcome everyone to the Processa Pharmaceuticals’ announced acquisition of Vidya Therapeutics. [Operator Instructions]

I would now like to turn the conference over to George Ng, CEO. You may begin.

George Ng
CEO & Director

Good morning, everyone, and thank you for joining us for our announcement of Processa’s acquisition of Vidya Therapeutics and the concurrent private placement financing.

I’m George Ng, CEO of Processa, and I’m delighted to introduce Sheila Gujrathi of Vidya Therapeutics, who, in connection with the transaction, has joined Processa’s Board of Directors. She will present details on Vidya and its focus on advancing BTK inhibitor therapies for immune-mediated diseases. You can access the press release issued this morning on the Investor Relations page of our website at www.processappharma.com (sic) [ www.processapharmaceuticals.com ].

Before we jump into the strategic details, I’ll direct your attention to the safe harbor slide currently on your screen. I’ll remind listeners that our comments today will include forward-looking statements, which are subject to various risks and uncertainties detailed in our SEC filings, including our annual report on Form 10-K for the year ended December 31, 2025, and quarterly report on Form 10-Q for the quarter ended March 31, 2026.

With that, I will now turn the call over to Sheila.

Sheila Gujrathi

Thank you, George, and thank you to everyone for joining us today. I’m Sheila Gujrathi, Founder of Vidya and newly appointed Director of Processa. Vidya is a clinical-stage biotechnology company focused on immune system and central nervous system diseases.

The acquisition is